

OAB symposium

主題: Predictive factors for successful mirabegron treatment and Taiwan experience

時間: 2016/07/09 (Sat.) 13:30 -17:00

地點: 台大國際會議中心 (room 203)

Time	Topics	Speaker	Moderators
13:30-13:40	Openings	郭漢崇 理事長	
Mirabegron treatment- Taiwan experience (I)			
13:40-14:10 (30mins)	Early Taiwan experience of mirabegron in treatment of OAB- switching from antimuscarinic to mirabegron, patient satisfaction and reasons of withdrawal (include Taiwan experience- switching study AM to BET)	廖俊厚 醫師	沈正煌 醫師
Mechanism of β-3 adrenoceptor agonist and clinical target on OAB			
14:10-14:40 (30 mins)	Mechanism of β -3 adrenoceptor agonist and potential clinical target on overactive bladder- OAB dry/wet? Phasic/terminal DO? BOO/OAB? Neurogenic DO? DHIC?	蒙 恩 醫師	林登龍 醫師
Mirabegron treatment- Taiwan experience (II)			
14:40-15:10 (30 mins)	Therapeutic efficacy of mirabegron, solifenacin, and combined mirabegron and solifenacin- will more drugs has a better improvement? (include Taiwan experience- 4-arm study)	王炯理 醫師	林鶴雄 醫師
15:10-15:30	Tea Break		
15:30-16:00 (30 mins)	Different dose of mirabegron in Treatment of OAB- what is the optimal dose of mirabegron for Asian people? (Include Taiwan study- BET TUA trail)	張嘉峰 醫師	莊耀吉 醫師
16:00-16:30 (30 mins)	Predictive factors for patients who may benefit from mirabegron treatment?	李偉嘉 醫師	余宏政 醫師
16:25-16:45 (20 mins)	Discussion	All	
16:45-17:00	Closing remarks	郭漢崇 理事長	